Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYRS News Highlights
- SYRS's 30 day story count now stands at 10.
- Over the past 19 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ACI, ASH and MOTS are the most mentioned tickers in articles about SYRS.
Latest SYRS News From Around the Web
Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Syros to Participate at Piper Sandler 34th Annual Healthcare ConferenceCAMBRIDGE, Mass., November 22, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Management will also be available for one-on-one meetings. Details are as follows: |
Analysts Are Bullish on These Healthcare Stocks: Syros Pharmaceuticals (SYRS), Motus Gi Holdings (MOTS)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRS – Research Report), Motus Gi Holdings (MOTS – Research Report) and TransCode Therapeutics (RNAZ – Research Report) with bullish sentiments. Syros Pharmaceuticals (SYRS) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals today and set a price target of $20.00. The company's shares closed last Monday at $3.66, close to its 52-week low of $3.52. According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 24.4% success rate. |
Brookline Capital Markets Remains a Buy on Syros Pharmaceuticals (SYRS)Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Syros Pharmaceuticals (SYRS - Research Report) today and set a price target of $60.00. The company's shares opened today at $3.91.According to TipRanks, R. Cann is an analyst with an average return of -1.0% and a 43.39% success rate. R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and Syros Pharmaceuticals.Currently, the analyst consensus on Syros Pharmaceuticals is a Moderate Buy with an average price target of $43.50. |
Syros Pharmaceuticals, Inc. (SYRS) Reports Q3 Loss, Misses Revenue EstimatesSyros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateCAMBRIDGE, Mass., November 14, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update. |
Syros Pharmaceuticals Stock (NASDAQ:SYRS): Worse than a Powerball Lottery Ticket?Syros Pharmaceuticals (NASDAQ: SYRS) is one of those companies that any conscientious individual would root for but shouldn't necessarily invest their hard-earned capital in. Sure, it would be great to see Syros's clinical programs succeed, but cautious financial traders must acknowledge the odds and accept that failure is a possibility. So, I hate to say it, but I'm bearish on Syros Pharmaceuticals stock. I want you to think of SYRS stock like a ticket for the Powerball Lottery that's been in the headlines lately. Yes, you're betting small to possibly win big, but the likelihood of actually winning big is minuscule. |
Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022CAMBRIDGE, Mass., November 07, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update. |
Brookline Capital Markets Sticks to Their Buy Rating for Syros Pharmaceuticals (SYRS)In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Syros Pharmaceuticals (SYRS - Research Report), with a price target of $60.00. The company's shares closed last Friday at $4.16.R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and Syros Pharmaceuticals. According to TipRanks, R. Cann has an average return of -3.4% and a 38.31% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syros Pharmaceuticals with a $39.25 average price target. |
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., November 04, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 22,610 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual MeetingCAMBRIDGE, Mass., November 03, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA. The SELECT-AML-1 trial is evaluating tamibarotene, Syros’ first-in-class selective retinoic aci |